Combination therapy for the treatment of cancer

Abstract

The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof.

1 .- 42 . (canceled) 
     
     
         43 . A method of treating HR+ breast cancer in a human, comprising administering to the human Compound A1, or a pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
       
       and an aromatase inhibitor. 
     
     
         44 . The method of  claim 43 , wherein the aromatase inhibitor is letrozole, anastrozole, or exemestane. 
     
     
         45 . The method of  claim 43 , wherein the aromatase inhibitor is letrozole, 
     
     
         46 . The method of  claim 43 , wherein the aromatase inhibitor anastrozole. 
     
     
         47 . The method of  claim 43 , wherein the aromatase inhibitor is exemestane.